Chronic hepatitis B: Treatment alert

Ting Tsung Chang, Hua Zhuang, Jidong Jia, Nancy Wai Yee Leung, Richard Guan, S. M.Wasim Jafri, Laurentius A. Lesmana, Yun Fan Liaw, Stephen Locarnini, Masao Omata, Jose D. Sollano, Dong Jin Suh, Varocha Mahachai, Pham Hoang Phiet, Shiv K. Sarin, Guangbi Yao, Seung Kew Yoon

研究成果: Review article同行評審

26 引文 斯高帕斯(Scopus)


Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20000IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.

頁(從 - 到)47-58
期刊Liver International
發行號SUPPL. 2
出版狀態Published - 2006 12月

All Science Journal Classification (ASJC) codes

  • 肝病


深入研究「Chronic hepatitis B: Treatment alert」主題。共同形成了獨特的指紋。